Critical Reviews in Oncology Hematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Evolution in sentinel lymph node biopsy in breast cancer
Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging in clinically node-negative (cN0) breast cancer patients without neoadjuvant chemotherapy (NAC). The application of SLNB in patients receiving NAC has also been explored. Evidence supports its use after NAC in pretreatment cN0 patients. Nonetheless, its routine use in all the pretreatment node-positive patients who become cN0 after NAC is unjustified due to the unacceptably high false-negative rate, which can be improved in a subset of patients. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 20, 2017 Category: Cancer & Oncology Authors: Si-Qi Qiu, Guo-Jun Zhang, Liesbeth Jansen, Jakob de Vries, Carolien P. Schr öder, Elisabeth G.E. de Vries, Gooitzen M. van Dam Tags: Review Source Type: research

Combination immunotherapy strategies in advanced Non-Small Cell Lung Cancer (NSCLC): Does biological rationale meet clinical needs?
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 18, 2017 Category: Cancer & Oncology Authors: Ilaria Attili, Antonio Passaro, Alberto Pavan, PierFranco Conte, Filippo De Marinis, Laura Bonanno Tags: Review Source Type: research

Critical Risk-Benefit Assessment of the Novel Anti-Cancer Aurora A Kinase Inhibitor Alisertib (MLN8237): A Comprehensive Review of the Clinical Data
Many current anticancer chemotherapeutics suffer from significant side effects, which have led to the exploration of more targeted therapies. This resulted in the exploration of inhibitors of Aurora A kinase as a potential anti-cancer treatment. Alisertib (MLN8237) has proven to be a potent Aurora A kinase inhibitor that had the highest safety profile among its therapeutic family. Phase I/II/III clinical trials with Alisertib have been carried out and reported promising efficacy, yet serious side effects. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 16, 2017 Category: Cancer & Oncology Authors: Yaman Tayyar, Luqman Jubair, Sora Fallaha, Nigel McMillan Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 14, 2017 Category: Cancer & Oncology Source Type: research

Review: Effectiveness of implementation strategies to increase physical activity uptake during and after cancer treatment
The purpose of this review was to assess the effectiveness of different strategies to implement physical activity during and after cancer treatment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 11, 2017 Category: Cancer & Oncology Authors: C. IJsbrandy, P.B. Ottevanger, M. Tsekou Diogeni, W.R. Gerritsen, W.H. van Harten, R.P.M.G. Hermens Source Type: research

Genistein: its role in metabolic diseases and cancer
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 11, 2017 Category: Cancer & Oncology Authors: Vidya Mukund, Dhruv Mukund, Vinay Sharma, Mastan Mannarapu, Afroz Alam Source Type: research

Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
Targeting immune checkpoints is a novel approach in cancer therapy. This strategy may trigger immune related adverse events (irAE). We hypothesize that the incidence of irAE will be greater in patients receiving immune checkpoint inhibitors (ICI) targeting only immune cells compared to those that also target tumor cells (PD-L1). In addition, we compared the specific irAE profile and overall response rate (ORR) for each ICI by target(s). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 8, 2017 Category: Cancer & Oncology Authors: B. El Osta, F. Hu, R. Sadek, R. Chintalapally, S.-C. Tang Tags: Review Source Type: research

Evaluation and management of skeletal disease in cancer care
Recently, there have been considerable advancements in cancer therapies thereby prolonging the life of cancer survivors. However, these recent advancements present new challenges in the management of bone disease in cancer survivors. Bone acts as a fertile soil for cancer seeding and bone health is often compromised because of increased inflammatory cytokines in cancer, direct cancer metastasis and toxic effects of anti-cancer therapies. This effect is more pronounced in elderly population who already have compromised bone mineral density leading to increased skeletal related events and bone pain. (Source: Critical Reviews...
Source: Critical Reviews in Oncology Hematology - September 8, 2017 Category: Cancer & Oncology Authors: Anuhya Kommalapati, Mary Angelynne Esquivel, Ricardo Correa, Sri Harsha Tella Source Type: research

Do alcoholic beverages, obesity and other nutritional factors modify the risk of familial colorectal cancer? A systematic review
Individuals with family history of colorectal cancer are at higher risk of colorectal cancer than the general population. Until now, guidelines for familial colorectal cancer risk have only pointed at early diagnosis efforts via screening tests and surveillance, and payed scarce or no attention to lowering exposure to modifiable risk factors, notably nutritional factors. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 7, 2017 Category: Cancer & Oncology Authors: Anthony Fardet, Nathalie Druesne-Pecollo, Mathilde Touvier, Paule Latino-Martel Source Type: research

Clinical pharmacology of anti-angiogenic drugs in oncology
Abnormal vasculature proliferation is one of the so-called hallmarks of cancer. Angiogenesis inhibitor therapies are one of the major breakthroughs in cancer treatment in the last two decades. Two types of anti-angiogenics have been approved: monoclonal antibodies and derivatives, which are injected and target the extracellular part of a receptor, and protein kinase inhibitors, which are orally taken small molecules targeting the intra-cellular Adenosine Triphosphate −pocket of different kinases. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - September 1, 2017 Category: Cancer & Oncology Authors: P. Gougis, J. Wassermann, J.P. Spano, N. Keynan, C. Funck-Brentano, J.E. Salem Source Type: research

Targeting androgen-independent pathways: new chances for patients with prostate cancer?
Prostate cancer (PC) accounts for 1 in 5 new diagnoses of cancer in the United States of America and, despite the recent improvements, this neoplasm still causes more than 26,000 deaths per year (Siegel et al., 2016). The prostate gland is constituted both of basal and luminal epithelium arranged in a fibro-muscular stromal network (Packer and Maitland, 2016). Based on the observation that human PC are mostly luminal-like adenocarcinomas, the luminal origin of PC is supported by several studies (Wang et al., 2009; Wang et al., 2014). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 28, 2017 Category: Cancer & Oncology Authors: C. Cattrini, E. Zanardi, G. Vallome, A. Cavo, L. Cerbone, A. Di Meglio, C. Fabbroni, M.M. Latocca, F. Rizzo, C. Messina, A. Rubagotti, P. Barboro, F. Boccardo Source Type: research

Towards personalized medicine of colorectal cancer
Efforts in colorectal cancer (CRC) research aim to improve early detection and treatment for metastatic stages which could translate into better prognosis of this disease. One of the major challenges that hinder these efforts is the heterogeneous nature of CRC and involvement of diverse molecular pathways. New large-scale ‘omics’ technologies are making it possible to generate, analyze and interpret biological data from molecular determinants of CRC. The developments of sophisticated computational analyses would allow information from different omics platforms to be integrated, thus providing new insights into th e bio...
Source: Critical Reviews in Oncology Hematology - August 26, 2017 Category: Cancer & Oncology Authors: Mohammad Azhar Aziz, Zeyad Yousef, Ayman Saleh, Sameer Mohammad, Bandar Al Knawy Tags: Review Source Type: research

Distance-delivered physical activity interventions for childhood cancer survivors: A systematic review and meta-analysis
The five-yearsurvival rate for childhood cancer has increased from 50% in the 1970s to over 80% in 2016 (Ries Smith et al., 1999; Smith et al., 2010). Advancements in treatments and supportive care have contributed to this increase in survival, with the current number of childhood cancer survivors (CCS) estimated at over 380,000 in the United States alone (Ward et al., 2014). Treatments for childhood cancer can result in a range of medical late-effects, with up to three-quarters of CCS experiencing a chronic illness as a result of their cancer or treatment (Mertens et al., 2001). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 26, 2017 Category: Cancer & Oncology Authors: David Mizrahi, Claire E. Wakefield, Joanna E. Fardell, Veronica F. Quinn, Qishan Lim, Briana K. Clifford, David Simar, Kirsten K. Ness, Richard J. Cohn Tags: Review Source Type: research

Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 25, 2017 Category: Cancer & Oncology Authors: Rui Pedro Marques, Gon çalo S Duarte, Carmelo Sterrantino, Helena Luna Pais, António Quintela, Ana Paula Martins, João Costa Source Type: research

Developing drugs in cancer-related bone pain
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - August 25, 2017 Category: Cancer & Oncology Authors: Maurizio Lucchesi, Gaetano Lanzetta, Andrea Antonuzzo, Antonio Rozzi, Iacopo Sardi, Claudio Favre, Carla Ida Ripamonti, Daniele Santini, Grazia Armento Source Type: research